LELON: Board of Directors Resolves Not to Proceed with Private Placement Capital Increase Approved by 2025 Shareholder Meeting
LELON's Board of Directors has decided not to proceed with the private placement cash capital increase plan, which was approved by the shareholder meeting on June 25, 2025, as its one-year implementation period is approaching its expiration.
📋 Article Processing Timeline
- 📰 Published: May 13, 2026 at 09:00
- 🔍 Collected: May 14, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: May 14, 2026 at 08:59 (59 min after Collected)
1. Date of Board of Directors' resolution change: 2026/05/13
2. Original planned effective date of declaration: 2025/06/25
3. Date of subsequent issuance: Not applicable
4. Reason for change: The company's private placement cash capital increase plan, approved by the shareholders' meeting on June 25, 2025, will expire on June 24, 2026. As the deadline approaches, the Board of Directors has resolved not to proceed with the plan.
5. Fund-raising plan before and after previous changes: Not applicable
6. Expected progress of execution: Not applicable
7. Expected completion date: Not applicable
8. Expected potential benefits: Not applicable
9. Difference from original expected benefits: Not applicable
10. Impact of this change on shareholders' equity: Not applicable
11. Summary of opinion from original lead underwriter: Not applicable
12. Other matters that should be specified: None
2. Original planned effective date of declaration: 2025/06/25
3. Date of subsequent issuance: Not applicable
4. Reason for change: The company's private placement cash capital increase plan, approved by the shareholders' meeting on June 25, 2025, will expire on June 24, 2026. As the deadline approaches, the Board of Directors has resolved not to proceed with the plan.
5. Fund-raising plan before and after previous changes: Not applicable
6. Expected progress of execution: Not applicable
7. Expected completion date: Not applicable
8. Expected potential benefits: Not applicable
9. Difference from original expected benefits: Not applicable
10. Impact of this change on shareholders' equity: Not applicable
11. Summary of opinion from original lead underwriter: Not applicable
12. Other matters that should be specified: None